Last reviewed · How we verify
Enzymatic agent
The enzymatic agent developed by the University of Louisville is currently marketed, positioning it as an established player in its therapeutic segment. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The lack of reported revenue and key trial results highlights a significant risk in assessing the drug's market performance and clinical efficacy.
At a glance
| Generic name | Enzymatic agent |
|---|---|
| Sponsor | University of Louisville |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients (PHASE2)
- Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study
- LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery (PHASE2)
- BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer (NA)
- hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (PHASE2)
- Toxicological Analysis in Chemical Submission
- Cell-Based Therapy for White Matter Repair in Periventricular Leukomalacia (EARLY_PHASE1)
- LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enzymatic agent CI brief — competitive landscape report
- Enzymatic agent updates RSS · CI watch RSS
- University of Louisville portfolio CI